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There is a clear need for drug treatments to be selected according to the
characteristics of an individual patient, in order to improve efficacy and reduce
the number and severity of adverse drug reactions. One of the main enzymes to
take into account in pharmacogenomics is catechol O-methyltransferase (COMT),
which catalyzes the transfer of a methyl group from S-adenosylmethionine to
catechols and catecholamines, like the neurotransmitters dopamine, epinephrine, and
norepinephrine. Although, most of this enzyme is associated to intracellular vesicles,
recently it has also been detected in extracellular vesicles secreted by hepatocytes
and in serum circulating vesicles. COMT has implications in many neurological
and psychiatric disorders like Parkinson’s disease, chronic fatigue, pain response,
schizophrenia, and bipolar disorders. Remarkably, genetic variations of COMT affect
its activity and are associated to various human disorders from psychiatric diseases
to estrogen-induced cancers. Consequently, the establishment of new methods to
evaluate COMT activity is an important aspect to investigate the biology of this
drug-metabolizing enzyme. Herein, we have developed a sensitive and selective method
to determine COMT activity. We first optimized the activity in rat liver incubated with two
different substrates; norepinephrine and dopamine. The enzymatically formed products
(normetanephrine and 3-methoxytyramine, respectively) were extracted by solid-phase
extraction using weak cation exchange cartridges, chromatographically separated, and
detected and quantified using a mass spectrometer. The range of quantitation for both
products was from 0.005 to 25 µg/mL. This methodology offers acceptable recovery
for both enzymatic products (≥75%) and good accuracy and precision (≤15%). The
lower limit of quantifications were 0.01 and 0.005 µM for 3-methoxytyramine and
normetanephrine, respectively. Importantly, this sensitive assay was able to detect
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the presence of COMT activity in extracellular vesicles secreted by hepatocytes
supporting a potential role of these vesicles in catecholamines and catecholestrogens
metabolisms. In addition, the presence of COMT activity in extracellular vesicles opens
new possibilities to develop tools to evaluate personalized drug response in a low
invasive manner.
Keywords: COMT assay, SPE–UPLC–MS/MS method, catecholamine, norepinephrine, dopamine, diclofenac,
exosomes, extracellular vesicles
INTRODUCTION
COMT (EC 2.1.1.6) is an enzyme that catalyzes the transfer
of a methyl group from S-adenosyl-L-methionine to one
of the hydroxyls of a catechol in the presence of Mg2+
(for review see Männistö and Kaakkola, 1999; Pihlavisto
and Reenilä, 2002). COMT plays an important role in
the metabolism of opioids, catechol drugs, catecholamine
neurotransmitters, and catecholestrogens (Bell et al., 2015;
Zhang et al., 2015). COMT can be found in most mammalian
tissues (e.g., in brain; regulating the amounts of norepinephrine,
dopamine, and epinephrine), with highest activities in liver,
kidney, and intestinal tract, where COMT may modulate the
dopaminergic tone.
The structural organization of the COMT gene has been
reviewed in detail by Lundström et al. (1995). There is
one single gene for COMT, which codes for both soluble
COMT (S-COMT; 24 kDa) and membrane-bound COMT
(MB-COMT; 28 kDa). S-COMT is located in the cytosol
and MB-COMT is anchored to the rough endoplasmic
reticulum (Ulmanen et al., 1997; Myöhänen et al., 2010).
Although, the catalytic amino acid sequences of the two
forms are identical, the kinetic properties and in vitro
regioselectivity of the enzymes are different. MB-COMT
has higher affinity for catechol substrates and for S-adenosyl-
L-methionine coenzyme (Lotta et al., 1995). Interestingly, this
enzyme has also been detected in extracellular vesicles (EVs)
secreted by hepatocytes (Conde-Vancells et al., 2008) and
in serum circulating vesicles (Rodríguez-Suárez et al., 2014)
suggesting a possible role of these vesicles in the metabolism
of catecholamine neurotransmitters and catecholestrogens
metabolisms.
Various pharmacogenetics studies have revealed that some
single nucleotide polymorphisms of COMT gene can be very
important to drug personalized treatment. The most widely
studied variant is a G to A nucleotide substitution resulting
in an amino acid change from valine to methionine at codon
158 (Val158Met) decreases the thermal stability of the COMT
protein, resulting in a two- to four-fold decrease in the enzymatic
activity (Lachman et al., 1996; Zhang et al., 2009). Variations in
the activity of COMT influence various human disorders from
psychiatric diseases to estrogen-induced cancers (Cavalieri and
Rogan, 2006; Cavalieri et al., 2006; Tunbridge et al., 2006). In
addition, COMT is responsible for the metabolism of drugs,
therefore, variability in its activity has been shown to modulate
the efficacy of some drugs such as antidepressants and opioids (Ji
et al., 2012; Kapur et al., 2014).
Thus, the interest in evaluating the intracellular and
extracellular activity of COMT is increasing and reliable,
sensitive, and rapid analytical COMT assays are highly demanded
by clinician and pharmaceutical agencies in order to personalize
drug administration and avoid adverse effects of drugs. In
addition, for the measurement of COMT activity in various
disease states or disorders, for the determination of structure–
activity relationships of COMT or for the testing of efficacy of
new COMT inhibitors candidates used to increase the efficacy of
L-DOPA in the treatment of Parkinson’s disease (Mueller, 2015).
A general COMT assay consists of the handling of the sample
and incubation with the substrates followed by separation and
detection of the reaction products. To date, a variety of COMT
enzyme assays have been developed (Pihlavisto and Reenilä,
2002; Aoyama et al., 2005; Masuda et al., 2006; Hirano et al.,
2007; Reenilä and Rauhala, 2010; Kimos et al., 2016). However,
to our knowledge, none of them uses ultraperformance liquid
chromatography–tandem mass spectrometry (UPLC–MS/MS).
Herein, we have developed a method for the determination
of COMT activity in vitro using norepineprine or dopamine
as endogenous native substrates, which are metabolized to
normetanephrine and 3-methoxytyramine, respectively. To
develop a robust, sensitive and selective method we used rat
liver extracts, and once optimized, the method was applied to
evaluate COMT activity in a more challenging samples such as
EVs secreted by hepatocytes under normal and diclofenac-treated
conditions.
MATERIALS AND METHODS
Development of SPE-UPLC-MS Method
Rat Liver Extract
The in vitro experiments described in this study were performed
using six Wistar rat livers of 12-weeks obtained from Harlan
Laboratories (Indianapolis, IN, USA). Livers were cut on dry
ice and aliquoted into ∼50 mg. Aliquots were homogenized
with a Precellys homogenizer from Thermo Fisher Scientific
Inc. (Waltham, MA, USA), using soft tissue homogenizing
beads (CK14. Thermo Fisher Scientific Inc.). Each aliquot was
homogenized in 2 × 20 s cycles at 6000 rpm in 500 µL of 50
mM sodium phosphate buffer (pH 7.4) containing 10% glycerol.
Subsequently, the resulting homogenates were transferred to
fresh tubes and centrifuged at 14,000 rpm for 30 min (4◦C). A
pooled sample, prepared by mixing equal aliquots of each liver
extract, was used to optimize the UPLC–MS/MS method. The
protein final concentration of the liver extracts was determined
by Bradford assay (Bradford, 1976) (Bio-Rad Laboratories,
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Inc) using bovine serum albumin as standard (Thermo Fisher
Scientific Inc). All the animal experimentation was conducted
in accordance with the Spanish Guide for the Care and Use of
Laboratory Animals1. Animal protocols were approved by the
CIC bioGUNE Institute and the regional Basque Country ethical
committee (ref. P-CBG-CBBA-3610).
COMT Enzymatic Assay
Mixtures consisted of liver extract (50 µg of protein) incubated
with 2 mM MgCl2, 200 µM S-adenosyl-L-methionine
(Abbott S.r.l. Campoverde, Italy) and the substrate 0.1 mM
norepinephrine (Tsunoda et al., 2002; Bonifácio and Soares-
da-Silva, 2003; Sigma-Aldrich Corp. St. Louis, MO, USA) or 2
mM dopamine (Levitt et al., 1982) (Dopamine hydrochloride.
Sigma-Aldrich Corp.) in a final volume of 300 µL of 50 mM
sodium phosphate buffer (pH 7.4). The enzymatic reaction
was performed for 1 h at 37◦C in a water bath. Standard stock
solutions of norepineprine and dopamine were prepared in
methanol/formic acid (99.9/0.1; v/v%) and the working solutions
by appropriate dilution in phosphate buffer. S-adenosyl-L-
methionine working solution was prepared directly in phosphate
buffer. Enzymatic reaction was stopped by the addition of 1
mL of acetonitrile/water/formic acid (75/23.8/1.2; v/v/v%).
Mixtures were shaken for 30 min at 4◦C and centrifuged at
14,000 rpm for 30 min (4◦C). The supernatant (1.1mL) was
reduced to dryness in a centrifugal vacuum concentrator (miVac
concentrator. Genevac SP Scientific; Warminster PA, USA).
Blank samples (liver extract without analyte) were prepared from
heat inactivated (10min at 95◦C) extract liver (50 µg of protein),
not-incubated and subjected to the treatment as previously
described.
Sample Preparation: Solid Phase Extraction
Solid Phase Extraction (SPE) was used to process the samples
prior to UPLC–MS/MS analysis. The SPE protocol included:
pretreatment of the samples, conditioning, and equilibration
of the cartridges, sample loading, washing, and elution of
the compounds of interest (Peaston et al., 2010). SPE 3cc
Oasis weak cation-exchange cartridges (60mg sorbent, 30 µm
particle size; Waters Corp., Milford, MA, USA) were conditioned
with 2.5 mL of methanol followed by 2.5 mL of ammonium
phosphate 10 mM (pH 6.5). Subsequently, samples reconstituted
in 1 mL of ammonium phosphate 10 mM (pH 6.5) were
run through the cartridges. The cartridges were then washed
with 3 mL of water, 2 mL of methanol, and 2 mL of
acetonitrile. The analytes of interest were eluted with 2 mL of
2% formic acid in acetonitrile/water (95/5; v/v%). The elution
solvent was evaporated to dryness in a centrifugal vacuum
concentrator and the residue was reconstituted in 300 µL of
acetonitrile/water/formic acid (60/39.9/0.1; v/v/v%). Finally, a
total volume of 2 µL was injected into the UPLC system.
The recoveries (or extraction efficiency of SPE method) of
normetanephrine and 3-methoxytyramine, at 2.5 µM, were
determined by comparisons of the peak areas of each of
the analytes in pre-extracted spiked blank samples (n = 4)
against post-extracted spiked blank samples (n = 4). Standard
stock solutions of normetanephrine (DL-Normetanephrine
1Royal Decree 1201/2005. Spanish Official State Gazette 252, 21st October 2005.
hydrochloride. Sigma-Aldrich Corp.) and 3-methoxytyramine
(3-Methoxytyramine hydrochloride. Sigma-Aldrich Corp.) were
prepared in methanol/formic acid (99.9/0.1; v/v%) and the
working solutions by appropriate dilution in ammonium
phosphate 10 mM (pH 6.5; for pre-extracted spiked samples)
and acetonitrile/water/formic acid (60/39.9/0.1; v/v/v%; for post-
extracted spiked samples).
Identification and Quantification of Enzymatically
Formed Normetanephrine and 3-Methoxytyramine
For COMT assay, the substrates (norepinephrine and
dopamine) and enzymatic products (normetanephrine and
3-methoxytyramine) were chromatographically separated using
an Acquity UPLC system (Waters Corp.). The system was
equipped with two binary solvent pumps, a cooled autosampler
(4◦C) with a 10 µL injection loop and a column oven (40◦C).
A 2.1 × 100 mm, 1.7 µm BEH amide column (Waters Corp.)
was used for separation of the analytes. Samples were injected
(Vload 2 µL) from deactivated total vials (Waters Corp.).
For liquid chromatography experiments, acetonitrile (LC-MS
Chromasolv grade; Riedel-de Haën, Seelz, Germany), formic acid
(analytical grade; Sigma), ammonium formate (analytical grade;
Sigma), and Milli-Q water obtained using a Millipore system
(Bedford, MA, USA) were used. A gradient was developed to
separate the analytes. Solvent A consisted of 99.5% water, 0.5%
formic acid, and 20 mM ammonium formate while solvent
B consisted of 29.5% water, 70% acetonitrile, 0.5% formic
acid, and 1 mM ammonium formate. The gradient was as
follows: from 5 to 50% A in 2.4 min, from 50 to 99.9% A in
0.2 min, constant at 99.9% A for 1.6 min, back to 5% A in
0.3 min, and constant at 5% A for 0.5 min. The flow rate was
0.25mL/min.
A Synapt G2-HDMS Time-of- fight (ToF) mass spectrometer
(Waters Corp.) was used for the detection of the analytes. The
mass spectrometer was operated in electrospray positive mode.
The following source parameters were used for the analysis:
capillary voltage 2500 V, sample cone voltage 25 V, extraction
cone voltage 5 V, desolvation temperature 450◦C, source
temperature 120◦C, cone gas flow 5 L/h, and desolvation gas flow
600 L/h. Ion optics were tuned to a resolution of 22.000 (FWHM)
for m/z 556. In order to guarantee mass accuracy a solution
of Leucine-Enkefaline acquired from Sigma-Aldrich Corp. [2
µg/mL in acetonitrile/water (50/50; v/v%) and 0.1% formic acid]
was infused into the source via a second electrospray probe at 10
µL/min and used for a lock mass. Every 30 s a lock mass scan was
recorded for 0.5 s. Analyte spectra were automatically corrected
for fluctuations in the lock mass. Initially, to develop the UPLC–
MS method the mass spectrometer was operated in normal
acquisition mode (50–1200Da) with a 0.2 s scan time. Then,
in order to reach an optimized Lower Limit of Quantification
(LLOQ) for normetanephrine and 3-methoxytyramine, the mass
spectrometer was operated in enhanced duty cycle mode. In this
mode, the explosion of ion bunches from the transfer T-WaveTM
collision cell and the pusher of the analyzer are synchronized
so that the duty cycle is optimal for a given m/z. In this case,
normetanephrine and 3-methoxytyramine were measured in
scan functions optimized for m/z 166 and m/z 151, respectively.
The time for these scan functions was 0.2 s.
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With regard to data analysis, extracted ion traces
were obtained for normetanephrine (m/z 166.086) and
3-methoxytyramine (m/z 151.075) with a 20mDa window,
subsequently smoothed (2 points, 2 iterations) and integrated
with QuanLynx software (Waters Corp.). The COMT activity
was expressed as nanomol of product formed in an hour per 50
µg of protein.
Evaluation of the Method
Preparation of calibration curves and quality controls
Calibrators were prepared from stock solutions 10 mM
normetanephrine and 10 mM 3-methoxytyramine in
acetonitrile/water/formic acid (60/39.9/0.1; v/v/v%). These
stocks were diluted to give a series of solutions (from 0.005 to
25 µM) that were used to reconstitute a blank pool at the step
immediately prior to chromatography. Six replicates of quality
controls samples at 1 and 10 µM were prepared following the
S-adenosyl-L-methionine procedure to evaluate the accuracy
and precision of the method.
Selectivity
The selectivity is the ability of the analytical method to
discriminate the analyte of interest from interferences. The
selectivity of the assay was assessed, using blank samples from
six different livers. Based on guidance for industry documents
(Guidance for Industry Bionalytical Method Validation,
2011; Guideline on bioanalytical method validation, 2011) an
interfering peak should be <20% of the mean peak area for
the LLOQ.
Matrix effect
The determination of ionization suppression (or enhancement)
by matrix extracts is important as this phenomenon
can severely affect the sensitivity and robustness of the
analytical method. The effect of matrix was also evaluated
for normetanephrine and 3-methoxytyramine in six different
livers comparing peak areas of neat standards and standards
spiked in blank samples prior to their injection into the
UPLC system. Solutions of each compound (1 and 10 µM in
acetonitrile/water/formic acid (60/39.9/0.1; v/v/v%) were directly
injected (neat standards) or added to blank samples (spiked
standards).
Application of the Method to Evaluate
COMT Activity in Intra- and Extracellular
Vesicles
Sample Preparation
Rat microsomes
For microsomes preparation, fresh or cultured rat hepatocytes
were collected and centrifuged at 800 rpm 5 min at 4◦C.
The obtained pellet was resuspended in 0.5 ml of 100
mM phosphateTris-HCl buffer (pH 7.4). The suspension was
transferred to a standard 2 mL tube containing 500mg of soft
tissue homogenizing beads (CK14; Thermo Fisher Scientific
Inc.). The solution was lysed with a Precellys R© 24 tissue
homogenizer (Thermo Fisher Scientific Inc.) in 2 × 20 s cycles
at 6000 rpm. The resulting homogenate was centrifuged at
15,000 × g during 15min at 4◦C. Supernatant was then
ultracentrifuged at 100,000 × g during 60 min at 4◦C. Resulting
microsomal pellet was solubilized in 50 mM sodium phosphate
buffer (pH 7.4) containing 10% glycerol. Protein concentration
was determined by Bradford assay using bovine serum albumin
as standard (Thermo Fisher Scientific Inc).
Extracellular vesicles
Production and isolation of EVs secreted by primary rat
hepatocytes were performed as described in Conde-Vancells
et al. (2008) and Rodríguez-Suárez et al. (2014). Briefly, rat
hepatocyte suspension was centrifuged at 400 rpm 3 min and
seeded in 24 collagen-coated dishes (150 mm) with collagen
type I from rat tail (BD Biosciences. San Jose, CA) at 20
million cells per dish. Cells were cultured in complete Dulbecco’s
modified eagle medium (DMEM, Gibco, Life technologies,
Heidelberg, Germany) supplemented with 10% (v/v) fetal bovine
serum (Gibco), streptomycin (0.1 mg/L. Lonza, Walkersville,
MD, USA), penicillin (100 U/mL. Lonza), and amphotericin-
B (0.25µg/mL, Lonza) for 4 h at 37◦C and 5% CO2. Then,
cells were washed twice with DPBS and incubated for 36 h
in complete DMEM containing 25 mM HEPES (previously
depleted from contaminating vesicles by overnight centrifugation
at 100,000 × g, 4◦C). The 24 collagen-coated dishes were
divided in 2 groups (12 dishes each group) and incubated
individually with no additives or with 400µMdiclofenac sodium
(Sigma-Aldrich). After 36 h incubation, media was collected and
EVs isolated. The 36 h-conditioned medium was centrifuged
at 500 × g during 10 min to remove lifted cells and large
cellular debris. The resultant supernatant was filtrated through
a 0.22 µm pore size filter system (Corning. NY USA), and
filtrated supernatant was ultracentrifuged 30 min at 10,000 ×
g 4◦C to remove large vesicles. The resultant supernatant was
ultracentrifuged at 100,000 × g 4◦C during 75 min to sediment
EVs (mostly exosomes and small microvesicles). The supernatant
was completely removed, and the sediment washed with DPBS
by repeating ultracentrifuged at 100,000 × g 4◦C during 75 min.
Final sediment containing the EVs was resuspended in a total
volume of 0.25 ml of 50 mM sodium phosphate buffer pH 7.4
with 10% glycerol.
Assay COMT Activity Application in Microsomes and
Hepatic Extracellular Vesicles
Mixtures containing protein extracts (50 µg) were incubated
with 2 mM MgCl2, 200 µM S-adenosyl-L-methionine, and 0.1
mM norepinephrine in a final volume of 300 µL of 50 mM
sodium phosphate buffer (pH 7.4). The enzymatic reactions were
performed by 1 h at 37◦C in a water bath. After incubation, the
mixtures were processed according to the above condition for the
SPE–UPLC–MS/MS analysis.
RESULTS
Optimization Method
Incubation Conditions
To optimize the incubation conditions for measuring COMT
enzymatic activity several parameters were evaluated including
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required supplements, pH, and temperature of the incubation
mixture, incubation time, and stability of the substrates and
products during the reaction period. For COMT activity, Mg2+
ions are essential, since they are coordinated to both of the
catecholic hydroxyls, to a water molecule and to three amino
acid residues in the catalytic site of COMT (Vidgren and Ovaska,
1997). Therefore, Mg2+ ions are routinely added to reaction
mixtures at 2 mM MgCl2. COMT assays are performed under
physiological conditions (pH 7.4 and temperature 37◦C). For
the independent measurement of MB-COMT and S-COMT
activity different approaches have been employed (Tsunoda
et al., 2002). These include separation of the two forms by
differential centrifugation and use of two different substrate
concentrations and pH. In the present work, to simplify the assay
we have focused on the detection of MB-COMT activity and
consequently the optimal conditions established for MB-COMT
were used. Regarding the substrate, a wide variety of them are
available (Männistö and Kaakkola, 1999; Tsunoda et al., 2002).
In our case, two endogenous substrates (norepinephrine and
dopamine) were used. The use of endogenous substrates
provides relevant information on how COMT activity
works in vivo compared to other methods using artificial
substrates.
Sample Preparation: SPE Method Development
Currently, protein precipitation is the most widely employed
sample preparation technique in enzymatic assays, when to liquid
chromatography–mass spectrometry is used. However, in the
present work, only this technique was found be inappropriate.
Deposit of the salts were found in the ion source and cone using
only this kind of extraction, which brought about the decrease of
sensitivity and everyday clearance as well as column damage. To
avoid these problems, we decided to process the samples prior to
UPLC–MS/MS analysis using SPE. SPE extraction has advantages
over traditional extraction methods such as increased extraction
efficiency, higher selectivity, or greater reproducibility. If the
interferences were removed as part of the sample preparation,
then the analytes of interest could be analyzed with a more robust
method. Thus, after incubation, enzymatically formed products
(normetanephrine and 3-methoxytyramine) were isolated using
weak cation-exchange bound silica cartridges. In this system, the
main retention mechanism of the compounds of interest is based
mainly on the electrostatic attraction of the charged functional
group of the compounds to the charged group bonded to the
silica surface. The weak cation-exchange SPE material contains
an aliphatic carboxylic acid group bonded to the silica surface.
This carboxylic acid group is a weak anion and has a pKa of about
4.8. It will be negatively charged in solutions of at least 2 pH units
above this value, and will isolate cations if the pH is one at which
they are both charged. To improve ion exchange interactions on
weak cation-exchange, in the case of cationic compounds the pH
should be at least 2 pH units below the pKa (normetanephrine
and 3-methoxytyramine have a pKa of 9.1 and 9.6, respectively).
At low pH, the sorbent will be un-ionized, which shuts off the ion-
exchange mechanism. Therefore, an acidic solution (2% formic
acid) was used to elute the analytes of interest (normetanephrine
and 3-methoxytyramine). The recoveries (or extraction efficiency
of SPE method) of normetanephrine and 3-methoxytyramine
were 75 and 82%, respectively. These recoveries were in the
acceptable range for routine LC-MS analysis2.
UPLC–MS/MS Method Performance
We used an amide column to separate norepinephrine and
normetanephrine and dopamine and 3-methoxytyramine. This
column provides enhanced peak symmetry and strong retention
characteristics for these highly polar low molecular weight
bases (Grumbach and Fountain, 2010). Considering the strong
dependence of chromatographic behavior on the mobile phase
buffer, different concentrations of ammonium formate were
tested for their effect on the retention of the analytes (data not
shown). In the absence of ammonium formate the peak shapes
were broad and unregulated. The pH value of the buffer may
also have influence on the chromatographic behavior of analytes.
0.5% formic acid was used; under these conditions, the analytes
were positively charged and the substrates and the products were
completely separated (Table 1).
The Figures 1, 2 show the chromatograms of pairs
norepinephrine/normetanephrine and dopamine/3-
methoxytyramine, respectively. In the spectra of norepinephrine
and normetanephrine the ions corresponding to [M+H-H2O]+
were represented as base peak, whereas in the case of dopamine
and 3-methoxytyramine a loss of one molecule of ammonia was
TABLE 1 | COMT enzymatic assay: substrates and products.
Compound Structure and formula [M + H]+ Base peak tr
(m/z) min
Dopamine 154.086 137.063
[M+H-NH3]
+
1.3
3-Methoxytyramine 168.102 151.075
[M+H-NH3]
+
1.1
Norepinephrine 170.081 152.071
[M+H-H2O]
+
1.6
Normetanephrine 184.097 166.086
[M+H-H2O]
+
1.3
2Method validation and quality control procedures for pesticide residues analysis
in food and feed (2012). Document N◦SANCO/12495/2011.
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observed, forming the predominant ion [M+H-NH3]+ (Zhang
et al., 2007; Peaston et al., 2010).
As part of method development, the evaluation of matrix
effect on the quantitative analysis was estimated. Co-
eluting matrix components, which are not observed in the
chromatogram, can have a detrimental effect on the analysis.
Matrix effect was assessed in different livers and no ion
suppression (or ion enhancement) was observed.
The selectivity of the method was also evaluated and no
peaks (interferences) were observed at the retention time of
normetanephrine and 3-methoxytyramine. The good selectivity
achieved could be due to several reasons. SPE procedure used
was highly selective. In addition, the samples were analyzed
by UPLC-MS/MS using a ToF mass spectrometer. UPLC was
manufactured for the use of columns with sub-2 µm particles.
These particles provide more resolution and more speed. Due
FIGURE 1 | Representative chromatograms obtained from blank
sample spiked with (A) norepinephrine and (B) normetanephrine.
FIGURE 2 | Representative chromatograms obtained from extracted
blank sample spiked with (A) dopamine and (B) 3-methoxytyramine.
to better resolution and more narrow peaks, analytes will co-
elute less with interferences during ionization, so matrix effects
could be lower, or even eliminated (Van De Steene and Lambert,
2008). The ToF mass spectrometer used is characterized by
operating at a resolving power. Therefore, it gives accurate
masses for both parent and fragment ions and enables
the measurement of the elemental formula of a compound
achieving compound identification. In addition, the tandem
mass spectrometry provides more structural information, and
enhances selectivity. Thanks to the robustness of the method,
the use of internal standard was omitted and thus the method
simplified.
With regard to calibration curves, power fitting was used to
determine the relation between the signal (peak area) and sample
concentration (see Table 2). The LLOQ, defined as the lowest
concentration that can be measured with an acceptable level of
accuracy (±20%) and a precision below 20%, is included in the
Table 2.
The accuracy and precision were also assessed by determining
quality control samples at two concentration levels. Accuracy
was determined by comparing the mean observed concentration
to the theoretical concentration and expressed as the ratio in
percentage (% theoretical) and the precision by relative standard
deviation (RSD%). In both cases, accuracy and precision were
deemed to be acceptable (≤15%).
Test liver samples (n = 6) were injected in the same
batch together with quality control and calibration standard
samples. COMT activities in rat liver, incubated for 1 h with
norepinephrine or dopamine as a substrate, produced 6.2 ± 0.1
ng of normetanephrine and 6.9 ± 0.1 ng of 3-methoxytyramine,
respectively.
Method Application
COMT protein has been detected by proteomics and Western-
blotting in extracellular vesicles (EVs) secreted by hepatocytes
(Conde-Vancells et al., 2008) and in serum circulating vesicles
(Rodríguez-Suárez et al., 2014) suggesting a possible role of these
vesicles in the metabolism of catecholamine neurotransmitters
and catecholestrogensmetabolisms. However, in order to provide
more evidence to this possibility it is very important to elucidate
whether or not this enzyme is active in EVs. Here, we have
applied our method to evaluate COMT activity associated
to intracellular (microsomes) and extracellular (EVs) vesicles
obtained from hepatocytes without treatment or treated with
diclofenac (DCF) which is one of the most used over-the-counter
TABLE 2 | Concentration range, equation and LLOQ of calibration curves.
Product Range
(µM)
Equation power regression LLOQ (pmol)
3-Methoxytyramine 0.01–25 [Signal] = 10,411x
[concentration] 0.923
R2 > 0.99
0.02
Normetanephrine 0.005–25 [Signal] = 1177 ×
[concentration] 0.833
R2 > 0.99
0.01
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anti-inflammatory worldwide, ranking in the top 10 causes of
drug-induced liver injury3. Different samples were employed for
this analysis: microsomes isolated from primary rat hepatocytes
before seeding into dishes (Microsomes t0), microsomes isolated
from primary hepatocytes after being cultivated for 36 h
(Microsomes t36) with or without DCF, and extracellular vesicles
secreted to the tissue culture media by primary hepatocytes
incubated during 36 h (EVs t36) with or without DCF. All
enzymatic determinations were performed in triplicates. Our
method was able to detect COMT activity in all the samples
including EVs (Table 3). The higher activity levels were detected
in microsomes before putting the hepatocytes in culture. This
microsomal activity was reduced 3 and 5 times by the 36 h of
incubation of hepatocytes in the absence and presence of DCF,
respectively (Table 3). This reduction indicates that during the
36-h incubation period COMT activity is reduced inside the
cells; this effect is more severe in the case of the treatment
with drug. Interestingly, we were able to detect COMT activity
in EVs although the activity represented 1.1 and 2.3% of the
microsomal activity in normal and DCF-treatment, respectively
(Table 3).
DISCUSSION
Traditionally, COMT activity has been measured by liquid
chromatography coupled to different detectors: fluorescence,
radiochemical, electrochemical, or UV detectors (Amorim-
Barbosa et al., 2016). Although, these methods can be very
sensitive, they could require derivatization and, moreover,
possible interferences could be detected.
Mass spectrometry is a sensitive and powerful technology.
To our knowledge, there is only a COMT assay which
uses liquid chromatography coupled to mass spectrometry.
In this assay, Mitamura et al. (2000) determined specifically
the enzymatically formed guaiacol estrogens in rat brains by
liquid chromatography coupled to ion trap mass spectrometer
with atmospheric pressure chemical ionization and working in
mode selected-ion monitoring. In our case, we have developed
an alternative method to determine normetanephrine and
3-methoxytyramine, using another technology; in particular
UPLC-electrospray ionization-time of flight analyzer working in
TABLE 3 | COMT enzymatic activity in microsomes and extracellular
vesicles obtained from primary rat hepatocytes.
Sample 3-MT (nmol/mg/hour)*
Microsomes t0 78.80 ± 4.04
Microsomes t36 Control 24.70 ± 0.36
Microsomes t36 Diclofenac 13.80 ± 0.03
EVs t36 Control 0.27 ± 0.02
EVs t36 Diclofenac 0.32 ± 0.03
*mean ± SD, n = 3.
3Livertox. Clinical and Research Information on Drug Induced Liver Injury.
National library of medicine. Available online at: https://livertox.nlm.nih.gov//
Diclofenac.htm
tandem mass spectrometry mode. UPLC allows rapid analysis
(5min), for its part electrospray ionization is best suited
to ionic compounds with high polarity and tandem mass
spectrometry increases the specificity, sensitivity and throughput.
In addition, we have used (prior to analytical chromatography)
a double extraction with precipitation of protein and SPE. SPE
has become the most powerful technique available for rapid,
specific and selective sample preparation. SPE increases the
sensitivity for concentrating of analytes, removes interferences
to simplify chromatography and improves quantitation and
protect the analytical column from contaminants. Although,
we have performed the development of the method using
weak cation exchange cartridges, this SPE is available in
96-well plates. This format is ideal for high throughput
SPE allowing to process up to 96 samples in a couple of
minutes.
The present assay would be potentially suitable for the
detection of COMT activity not only in tissues, but also in
other biological matrices such as cells, or plasma. In addition,
although we have developed the method to detect specifically
normetanephrine and 3-methoxytyramine, taking into account
that weak cation-exchange SPE allows to concentrate strong bases
and quaternary amines and that amide column was especially
designed to retain polar compounds, other enzymatic substrates
with chemical structures similar could be analyzed using this
analytical method.
We have applied our method to evaluate COMT activity in
intracellular and extracellular vesicles.We have previously shown
by proteomics andWestern-blotting analyses that COMTprotein
is present in EVs secreted by hepatocytes (Conde-Vancells
et al., 2008) and also in serum circulating vesicles (Rodríguez-
Suárez et al., 2014). Now, by using our method we were
able to detect COMT activity in EVs secreted by hepatocytes.
This activity associated to EVs seems to be increased when
hepatocytes were treated with the drug diclofenac, which is one
of the most frequently used over-the-counter anti-inflammatory
worldwide, ranking in the top 10 causes of drug-induced liver
injury. Although, the activity levels that we found associated
to EVs were <3% of the intracellular activity, they could
have a patho-physiological role that certainly requires further
investigation.
There are increasing evidences that genetics variations
of enzymes have a significant impact in endogenous and
xenobiotics metabolisms what might mediate adverse effects
of drugs. In order to minimize these adverse effects, there
is a demand for drug treatments to be selected according
to the characteristics of an individual patient. COMT
enzyme is the most important enzyme in the metabolism
of catecholamines, which are modulators of nervous and
systemic responses. Our work, provide a sensitive, specific, and
quick method that in combination with pharmacogenomics and
pharmacometabolomics will be useful to define the different
genetic and metabolic modifiers of this enzyme. Furthermore,
the detection of COMT activity in extracellular vesicles able
to circulate through blood stream open new possibilities to
develop tools to evaluate personalized drug response in a low
invasive manner.
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As a conclusion, in this study we developed a highly specific
and sensitive UPLC–MS/MS method and showed for the first
time COMT activity associated with EVs.
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